Interstitial pneumonitis after hyperfractionated total body irradiation in hla-matched t-depleted bone marrow transplantation

Total body irradiation and pneumonitis risk: a review of outcomes

“…Previous literature has reported the absence of GVHD as contributing to a reduced risk of IP (Latini et al, 1992), and the presence of severe GVHD to be a significant risk factor for IP and early mortality (Weiner et al, 1986;Valls et al, 1993). Graft-versus-host disease was found on multivariate analysis of a randomised study to be significant for an increased risk of IP (Ozsahin et al, 1992), and a similar result was found in an earlier analysis (Torres et al, 1982).…”

“…Other retrospective studies have shown reduced risks of IP and fatal IP with fractionated TBI (Socie et al, 1991;Sutton et al, 1993). Hyperfractionated TBI schedules have found much reduced incidences of IP compared to single doses and standard fractionated doses (Cosset et al, 1989;Latini et al, 1992). The common feature of the above reviews of IP incidence and fractionation is that higher total doses are possible with fractionation, but the lungs remain the dose-limiting normal tissue for TBI.…”

“…Interstitial pneumonitis (IP) has a documented incidence ranging from 10 to 84% (Weiner et al, 1986). The development of IP is increased by various risk factors including infection, particular types of chemotherapy, the use of single fraction TBI at higher dose rates (Bortin et al, 1982;Deeg, 1983), higher total TBI lung dose (Keane et al, 1981;Torres et al, 1982), methotrexate administration post-transplant (Bortin et al, 1982;Weiner et al, 1986) and acute graft-versus-host disease (GVHD) (Torres et al, 1982;Cardozo et al, 1985;Weiner et al, 1986;Latini et al, 1992;Ozsahin et al, 1992Ozsahin et al, , 1994. The relative contributions of each are difficult to establish.…”

Intratracheal injection of manganese superoxide dismutase (MnSOD) plasmid/liposomes protects normal lung but not orthotopic tumors from irradiation

“…Seven days later, cultures were stained for LacZ and LacZ-positive colonies of у50 cells counted, and the data analyzed by linear quadratic and single-hit, multi-target models. 28 There was no significant difference in the irradiation survival of 3LL-LacZ cells mixed with normal lung cells or lung cells from mice previously injected with MnSOD-PL complex. Control C57BL/6 mice or C57BL/6J mice intratracheally injected with MnSOD-PL 24 h previously, received 5 Gy irradiation to both lungs.…”

“…As delivery of new inhalation gene therapy vectors becomes feasible, 25 use of radioprotective gene therapy programs in fractionated radiotherapy of thoracic tumor volumes or in total body irradiation patients 3 may become practical for reducing side-effects, including those mediated by lung tissue radiation damage. [26][27][28][29] Gene Therapy…”